Determination of pharmaceutical residues in wastewater using high performance liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry

•A method for the determination of 24 emerging pharmaceuticals has been developed.•The analysis of 21 samples revealed the occurrence of 20 selected pharmaceuticals.•The highest concentration was found for caffeine and acetaminophen. A multi-class method for the determination of 24 emerging pharmace...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical and biomedical analysis 2017-01, Vol.133, p.64-74
Hauptverfasser: Pugajeva, Iveta, Rusko, Janis, Perkons, Ingus, Lundanes, Elsa, Bartkevics, Vadims
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•A method for the determination of 24 emerging pharmaceuticals has been developed.•The analysis of 21 samples revealed the occurrence of 20 selected pharmaceuticals.•The highest concentration was found for caffeine and acetaminophen. A multi-class method for the determination of 24 emerging pharmaceutical residues has been developed and validated. The method is based on solid-phase extraction of wastewater samples using Strata-X cartridges followed by high performance liquid chromatography coupled to hybrid quadrupole − Orbitrap high resolution mass spectrometry (HPLC-Q-Orbitrap-HRMS). A single-laboratory validation procedure showed satisfactory analytical performance. The analysis of 21 samples collected at the wastewater treatment plant in Riga revealed the occurrence of 20 compounds of different therapeutic classes. The highest concentration was found for the central nervous system stimulator caffeine − up to 12μgL−1, the analgesic acetaminophen up to 4.2μgL−1, the antibiotic ciprofloxacin in the concentration range of 250–400ngL−1, and the non-steroidal anti-inflammatory drug (NSAID) ibuprofen at 100–325ngL−1.
ISSN:0731-7085
1873-264X
DOI:10.1016/j.jpba.2016.11.008